TRPC6 Antibody

What is TRPC6 and why is it a significant target for antibody-based research?

TRPC6 (Transient Receptor Potential Canonical Channel 6) is a non-selective cation channel activated by diacylglycerol that belongs to the TRP superfamily. It is expressed in numerous tissues and has been associated with several pathological conditions including focal segmental glomerulosclerosis, idiopathic pulmonary arterial hypertension, and cardiac hypertrophy . Its ubiquitous presence in lymphatic tissues and role in calcium signaling make it a critical target for immunological, renal, and neurological research .

TRPC6 channels permit the influx of calcium and other monovalent cations into cells, playing pivotal roles in various physiological processes including muscle contraction, neurotransmitter release, and cell proliferation . The channel consists of 931 amino acids with a calculated molecular weight of approximately 106 kDa .

Which tissues express TRPC6 and how can this inform antibody selection for tissue-specific studies?

Recent immunohistochemical studies have confirmed TRPC6 expression in a wide range of lymphatic tissues:

When selecting antibodies for tissue-specific studies, researchers should consider the differential expression patterns across tissues and cell types . For instance, studies focusing on renal podocytes may require different antibody dilutions than those examining splenic tissue due to varying expression levels.

What criteria should researchers use when selecting the appropriate TRPC6 antibody for their specific application?

Researchers should consider several factors when selecting TRPC6 antibodies:

• Application compatibility: Verify whether the antibody has been validated for your intended application (WB, IHC, IF/ICC, IP, ELISA, Flow Cytometry) .

• Species reactivity: Ensure the antibody recognizes TRPC6 in your species of interest. Many commercial antibodies have been validated for human and mouse samples, with some showing cross-reactivity with rat samples .

• Clonality:

  • Monoclonal antibodies (e.g., clone 3F2.H10.F2) offer high specificity and reproducibility

  • Polyclonal antibodies may provide higher sensitivity but potentially more background

  • Recombinant antibodies offer batch-to-batch consistency

• Epitope location: Consider antibodies targeting different regions (N-terminal vs. C-terminal) based on your research question .

• Validation method: Prioritize antibodies validated through multiple methods, particularly knockout validation .

How can researchers validate TRPC6 antibody specificity to ensure reliable experimental results?

Multiple validation approaches should be employed:

• Knockout validation: Test the antibody in tissues or cells where TRPC6 has been genetically deleted .

• Western blot analysis: Verify a single band at the expected molecular weight (100-110 kDa) .

• Multiple antibody approach: Use antibodies targeting different epitopes of TRPC6 to confirm consistent localization patterns .

• Negative controls: Include negative controls (e.g., rabbit serum instead of TRPC6 antibodies) in each staining run .

What are the optimal immunohistochemistry protocols for TRPC6 detection in different tissue types?

Based on published methodologies, the following protocol is recommended for TRPC6 detection:

• Tissue preparation:

  • Fix tissues in 4% paraformaldehyde

  • Process and embed in paraffin

  • Section at 3-5 μm thickness

• Antigen retrieval:

  • Option A: TE buffer pH 9.0 (recommended for human placenta)

  • Option B: Citrate buffer pH 6.0 (alternative method)

• Antibody dilutions and incubation:

  • Primary antibody: 1:50-1:500 dilution (optimize for specific tissue type)

  • Incubation: 10-12 hours at room temperature in a humidity chamber

  • Secondary antibody: HRP-conjugated anti-rabbit/mouse IgG (1:500)

• Detection system:

  • DAB chromogen for brightfield microscopy

  • Fluorophore-conjugated secondary antibodies for immunofluorescence

• Tissue-specific considerations:

  • Lymphatic tissues: Higher antibody dilutions may be required for tonsil tissue due to stronger expression

  • Renal tissue: Special attention to glomerular slit diaphragm regions

  • Vascular tissues: Focus on endothelial versus smooth muscle staining patterns

What are the recommended protocols for detecting TRPC6 in cultured cells using immunofluorescence?

For immunofluorescence in cultured cells, consider the following protocol:

• Cell preparation:

  • Grow cells on coverslips or chamber slides

  • Fix with 4% paraformaldehyde for 15 minutes at room temperature

  • Permeabilize with 0.1% Triton X-100 for 10 minutes

• Antibody dilutions:

  • Primary antibody: 1:200-1:800 dilution in blocking buffer

  • Secondary antibody: Fluorophore-conjugated at 1:500 dilution

• Imaging parameters:

  • Use confocal microscopy for precise subcellular localization

  • Include co-staining with membrane markers to confirm surface expression

• Controls:

  • Include cells transfected with TRPC6 siRNA as negative controls

  • Use GFP-tagged TRPC6 transfected cells as positive controls

How can TRPC6 antibodies be used to investigate protein-protein interactions at the slit diaphragm in podocytes?

TRPC6 interacts with several slit diaphragm proteins in podocytes, and these interactions can be studied using:

• Co-immunoprecipitation (Co-IP):

  • Lyse cells/tissues with buffer containing 20 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% NP40, 1 mM EDTA, protease inhibitors

  • Incubate lysates with anti-TRPC6 antibody overnight

  • Add protein G-coupled beads for 2 hours

  • Wash and elute bound complexes

  • Analyze by western blotting for interacting proteins (nephrin, podocin, CD2AP)

• Proximity ligation assay:

  • Use antibodies against TRPC6 and potential interacting partners

  • Employ secondary antibodies with oligonucleotide probes

  • Signals are generated only when proteins are within 40 nm of each other

• Co-localization studies:

  • Use GFP-tagged TRPC6 in cultured podocytes

  • Stain with antibodies against nephrin, podocin, and CD2AP

  • Analyze co-localization using confocal microscopy

  • Quantify using Pearson's or Mander's coefficient

Research has demonstrated that TRPC6 interacts directly with podocin and nephrin, forming a complex essential for proper filtration barrier function in the kidney .

How can phosphorylation-specific TRPC6 antibodies be used to study channel regulation?

Phosphorylation-specific antibodies allow researchers to investigate post-translational modifications that regulate TRPC6 function:

• Key phosphorylation sites:

  • Y31 and Y284 are phosphorylated by Src family kinases

  • These phosphorylation events regulate TRPC6 surface expression

• Experimental approaches:

  • Use phospho-specific antibodies against pY31 and pY284 for western blotting

  • Combine with surface biotinylation to correlate phosphorylation with membrane localization

  • Treat samples with phosphatase inhibitors (e.g., vanadate) to preserve phosphorylation status

• Kinase inhibitor studies:

  • Pretreat samples with Src family kinase inhibitors (SU6656, PP2)

  • Monitor changes in TRPC6 phosphorylation and localization

  • Correlate with calcium imaging to assess channel function

• Mutational analysis:

  • Compare wild-type TRPC6 with phospho-deficient mutants (Y31F, Y284F)

  • Assess impact on PLC-γ1 binding and channel trafficking

How can TRPC6 antibodies be utilized to investigate its role in focal segmental glomerulosclerosis (FSGS)?

TRPC6 mutations have been linked to familial FSGS, making it an important research target:

• Expression analysis:

  • Compare TRPC6 expression levels and localization in normal versus FSGS kidney tissues

  • Use immunohistochemistry with validated antibodies at 1:50-1:500 dilution

  • Analyze both glomerular and tubular expression patterns

• Mutation-specific approaches:

  • Generate antibodies against common FSGS-associated TRPC6 mutations (P112Q, R895C, E897K)

  • Compare trafficking and localization of wild-type versus mutant TRPC6

• Functional correlation:

  • Combine immunolocalization with calcium imaging in podocytes

  • Assess correlation between TRPC6 levels, localization, and calcium influx

  • Use phospho-specific antibodies to monitor activation status

• Therapeutic targeting assessment:

  • Use TRPC6 antibodies to monitor changes in expression/localization after treatment with potential therapeutic agents

  • Consider both total TRPC6 and phosphorylated TRPC6 levels

What approaches can be used to study TRPC6 in neurodegenerative disorders like Alzheimer's disease?

Recent research has identified TRPC6's interaction with amyloid precursor protein (APP), suggesting a role in Alzheimer's disease:

• Co-localization studies:

  • Use dual immunofluorescence with anti-TRPC6 and anti-APP antibodies

  • Analyze co-localization in brain tissue sections from control and AD patients

• Protein interaction analysis:

  • Employ co-immunoprecipitation to detect TRPC6-APP interactions

  • Compare interaction strength in normal versus pathological samples

  • Use TRPC6 antibodies immobilized on appropriate matrices

• Functional implications:

  • Investigate TRPC6's role in inhibiting APP cleavage by γ-secretase

  • Design fusion peptides derived from TRPC6 for potential therapeutic applications

  • Use antibodies to monitor changes in TRPC6-APP interactions after peptide treatment

• Animal model studies:

  • Use TRPC6 antibodies to assess expression changes in AD mouse models

  • Compare plaque load and TRPC6 expression in APP/PS1 mice versus TRPC6 transgenic crosses

  • Correlate with behavioral and structural measures

How can researchers employ TRPC6 antibodies in studying its role in immune cell function and inflammation?

The ubiquitous presence of TRPC6 in lymphatic tissues suggests important immunological functions:

• Differential expression analysis:

  • Compare TRPC6 expression between B and T lymphocytes

  • Use flow cytometry with anti-TRPC6 antibodies (0.40 μg per 10^6 cells)

  • Correlate with activation markers in normal versus inflammatory conditions

• Calcium signaling in immune activation:

  • Use TRPC6 antibodies in combination with calcium imaging

  • Monitor TRPC6 expression changes during T-cell activation

  • Correlate with cytokine release profiles

• Lymphocyte migration studies:

  • Investigate TRPC6 in high endothelial venules and its role in leukocyte migration

  • Combine with intravital microscopy to visualize trafficking

• Sepsis research:

  • Compare TRPC6 expression in lymph nodes from normal versus septic patients

  • Use immunohistochemistry to analyze changes in expression patterns

  • Correlate with markers of cellular stress and inflammatory cytokines

What methodological considerations are important when using recombinant TRPC6 antibodies in multiplex assays?

Recombinant TRPC6 antibodies offer advantages for multiplex applications:

• Batch consistency benefits:

  • Recombinant production ensures unrivalled batch-to-batch consistency

  • Facilitates reliable longitudinal studies and reproducible results

• Conjugation considerations:

  • Use conjugation-ready formats (PBS only, BSA and azide free)

  • Store at -80°C to maintain integrity

  • Follow manufacturer's protocols for optimal conjugation conditions

• Matched pair selection:

  • Use validated matched antibody pairs for applications like cytometric bead arrays

  • Example: 84517-1-PBS (capture) and 84517-2-PBS (detection)

• Multiplexing optimization:

  • Titrate antibody concentrations for each target in the multiplex panel

  • Validate for cross-reactivity with other antibodies in the panel

  • Include appropriate isotype controls